Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | PRKCG | P05129 | 1/20 | 0.40 |
| ▸ | PRKCB | P05771 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | PRKCH | P24723 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3108390 | 1.00 | ALOX15 (0.61) | ALOX15ALDH1A1ACE2USP2TDP1 | |
| SCHEMBL3125002 | 1.00 | ALOX15 (0.61) | ALOX15ALDH1A1ACE2USP2TDP1 | |
| SCHEMBL11041920 | 0.98 | ALOX15 (0.59) | ALOX15ALDH1A1ACE2USP2TDP1 | |
| SCHEMBL2840564 | 0.98 | ALOX15 (0.59) | ALOX15ALDH1A1ACE2USP2TDP1 | |
| SCHEMBL1200446 | 0.94 | ALOX15 (0.63) | ALOX15ALDH1A1ACE2USP2TDP1 | |
| SCHEMBL1200445 | 0.94 | ALOX15 (0.63) | ALOX15ALDH1A1ACE2USP2TDP1 | |
| SCHEMBL11344150 | 0.85 | ALOX15 (0.53) | ALOX15ALDH1A1ACE2USP2TDP1 | |
| SCHEMBL1200047 | 0.85 | ALOX15 (0.68) | ALOX15ALDH1A1USP2TDP1TSHR | |
| SCHEMBL1200044 | 0.85 | ALOX15 (0.68) | ALOX15ALDH1A1USP2TDP1TSHR | |
| SCHEMBL3117924 | 0.85 | ALOX15 (0.68) | ALOX15ALDH1A1USP2TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108329198-A | A kind of preparation method of tetrahydrochysene irisone | 梧州学院 | 2018-07-27 | — | — | CN | disclosed |
| EP-2172197-A1 | Octanoic acid derivative to treat fibromyalgia and other pains | Warner-Lambert Company LLC (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-1192125-B9 | MONO-SUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS | WARNER LAMBERT CO (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090203782-A1 | Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders | PFIZER INC. | 2009-08-13 | — | — | US | disclosed |
| EP-1192125-B1 | MONO-SUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS | WARNER LAMBERT CO (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080207755-A1 | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders | PFIZER INC | 2008-08-28 | — | — | US | disclosed |
| US-7381747-B2 | Alpha 2 delta ligands for post-traumatic stress disorder | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1840117-A1 | Mono- and disubstituted 3-propyl gamma-aminobutyric acids | Warner-Lambert Company LLC (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7189747-B2 | Method of treating noninflammatory cartilage damage | WARNER-LAMBERT COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| US-20070027212-A1 | ALPHA 2 DELTA LIGANDS FOR FIBROMYALGIA AND OTHER DISORDERS | PFIZER INC | 2007-02-01 | — | — | US | disclosed |
| US-20040063789-A1 | Mono-and disubstituted 3-propyl gamma-aminobutyric acids | BELLIOTTI THOMAS RICHARD (US) | 2004-04-01 | — | — | US | disclosed |
| US-6642398-B2 | Improving drug qualities such as bioavailability and stability | WARNER-LAMBERT COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-20030181523-A1 | Mono-and disubstituted 3-propyl gamma-aminobutyric acids | BELLIOTTI THOMAS RICHARD (US) | 2003-09-25 | — | — | US | disclosed |
| US-20030176504-A1 | Method of treating tinnitus | DOOLEY DAVID JAMES (US) | 2003-09-18 | — | — | US | disclosed |
| US-6620829-B2 | Administering a therapeutically effective amount of a GABA analog having characteristic of being an inhibitor of cartilage damage, or a pharmaceutically acceptable salt | WARNER-LAMBERT COMPANY | 2003-09-16 | — | — | US | disclosed |
| WO-2003063845-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-07 | — | — | WO | disclosed |
| US-20020072533-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2002-06-13 | — | — | US | disclosed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-1192125-A2 | MONO- AND DISUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000076958-A2 | MONO- AND DISUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203782-A1 | Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders | OPRD1, OPRL1, FFAR3 | ALOX15 390/4885ALDH1A1 775/4885ACE2 1460/4885 |
| US-20030176504-A1 | Method of treating tinnitus | ADRA2A, ADRA1A, ADRA1D | ALOX15 2410/4885ALDH1A1 137/4885ACE2 2933/4885 |
| US-20020072533-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | ALOX15 1587/4885ALDH1A1 30/4885ACE2 2874/4885 |
| US-20070027212-A1 | ALPHA 2 DELTA LIGANDS FOR FIBROMYALGIA AND OTHER DISORDERS | OPRD1, HCRTR2, OPRL1 | ALOX15 496/4885ALDH1A1 1174/4885ACE2 2919/4885 |
| US-20080207755-A1 | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders | OPRD1, OPRL1, FFAR3 | ALOX15 390/4885ALDH1A1 775/4885ACE2 1460/4885 |
| US-20040063789-A1 | Mono-and disubstituted 3-propyl gamma-aminobutyric acids | GABRB1, GABRA1, GABRB3 | ALOX15 412/4885ALDH1A1 311/4885ACE2 4663/4885 |
| US-20030181523-A1 | Mono-and disubstituted 3-propyl gamma-aminobutyric acids | GABRB1, GABRA1, GABRB3 | ALOX15 412/4885ALDH1A1 311/4885ACE2 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.